NCT04433988

Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Sadat City University · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

With potential antiviral effects on severe acute respiratory syndrome (SARS) and as a methyl-xanthine derived inhibitor of phosphodiesterase-4, pentoxifylline basically functions as a hemorrheologic agent for a better circulation and oxygenation and exerts unique effects on immune modulation, inflammation and oxidative stress. As the main regulator of cAMP metabolism, posphodiesterase-4 plays a key role in proinflammatory and immune cells. Pentoxifylline plays its anti-inflammatory role by reducing the production of proinflammatory cytokines such as TNF-a, IL-1 and IL-6. Given its unique impacts on immune modulation, homeostasis and fibrinolysis and its supportive effects on oxidative stress and organ failure, pentoxifylline can constitute a multipurpose and generally-safe adjuvant therapy for COVID-19 patients.

Conditions

• COVID

Interventions

Type	Name	Description
DRUG	Pentoxifylline	Pentoxifylline 400 mg SR tablet
DRUG	Placebo	Placebo tablet

Timeline

• Start date: 2022-11-13
• Primary completion: 2022-12-30
• Completion: 2022-12-30
• First posted: 2020-06-16
• Last updated: 2023-01-18

Locations

1 site across 1 country: Egypt